NKTX Nkarta Inc

$NKTX What fool is selling for this cheap? I’m not complaining I’m doubling down on my position at this discount.

$NKTX It will hit $1.70 sooner! watching this from few weeks.. will be a great long term buy for 5x!! Took a starter at $1.93!

$NKTX Now trading at 60% of cash value. Well defined range of $1.70 to $3.70 for two years. I guess I am bullish. 🤷‍♂️

$NKTX It's actually shocking to see it this low this close to data. It's back under cash value, strong management and imo strong hints that data will be good going from previous investor events. The fact data was delayed to put out a more comprehensive results also derisks it. The market seems to be dumping pre revenue stocks and the xbi is shaky so it's unfairly being beaten down. I'm adding more as RVR at these levels it too good to miss.

$NKTX Hard to understand this price level. These are the facts: • ~0.57x cash: $125M market cap vs ~$217M cash • Cash/share ~$3.0: ~70% upside to cash alone • No debt; runway into 2029 • Clean safety (25 patients): zero CRS, ICANS, GvHD, serious infections or deaths • Deep B-cell depletion plus moderate-to-major myositis responses • First CAR-NK in myositis • ARC abstracts look solid, backed by best in class scientists presenting data in 2 accepted oral talks. • NK approach already validated by Artiva (71% ACR50, Phase 3) • Partner/M&A optionality: off-the-shelf, redosable

$NKTX I believe we’re officially a month away from clinical data being presented at ACR. The market is undervaluing it but I’m loading up even more.

$NKTX down to $140M market cap vs $240M cash, which lasts into 2029 (don't think you can find that safe anywhere in biotech, factoring in near term data too). On top of that at a major support area going into key Nov data. I like my odds at this level when biotech turns around. In my opinion the "safest" biotechs to be in are ones that very strongly well capitalized, with long cash runways, no need to raise, and major near term data inflection points. NKTX checks all the boxes

$NKTX yep…IMO ..this is a good one …$2 is the magic area so start loading up within 5 cents plus or minus of that and you should be good

$NKTX Multi-year trend line hit again. Of the technicals are correct, it should be the last touch before it sky-rockets higher.

$NKTX anyone saw the Stifel presentation? Hastings said that the safety data is good because "ACR wouldn't give you an oral presentation about safety otherwise".

$NKTX Abstracts are published and preliminary data are presented. Safety is the main achievement. Overall the results look really promising. The main question is the efficacy compared to existing players.

$NKTX Short it on the way down before data, load up from the bottom then long it and ride the wave to $10. Is this plan?

$NKTX I’m adding more & more if the market keeps this gem at a discount added even more at $1.84

$NKTX This is confusing. If there is data to be presented then why not present it now to the share holders/public. Problem with some biotechs is they think this is academia and fresh data should go to a conf or peer-reviewed first.